Calidi Biotherapeutics Croissance future

Future contrôle des critères 0/6

Les bénéfices de Calidi Biotherapeutics devraient diminuer de 5.6% par an. Le BPA devrait augmenter de 61.3% par an.

Informations clés

-5.6%

Taux de croissance des bénéfices

61.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	21 Nov 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

NYSEAM:CLDI - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-26	N/A	-39	2
12/31/2025	N/A	-23	N/A	-32	2
12/31/2024	N/A	-25	N/A	-27	2
9/30/2024	N/A	-28	-20	-19	N/A
6/30/2024	N/A	-25	-28	-28	N/A
3/31/2024	N/A	-30	-28	-28	N/A
12/31/2023	N/A	-29	-28	-27	N/A
9/30/2023	N/A	-29	-26	-26	N/A
6/30/2023	N/A	-32	-17	-16	N/A
3/31/2023	N/A	-24	-15	-14	N/A
12/31/2022	0	-25	-14	-13	N/A
9/30/2022	0	-21	-12	-12	N/A
12/31/2021	0	-11	-8	-8	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CLDI devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CLDI devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CLDI devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de CLDI devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: CLDI ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CLDI devrait être élevé dans 3 ans

Calidi Biotherapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance